Table 1.

Neurologic course before enrollment in stem cell transplantation protocol

PatientAge, y/sexExpanded Disability Status Scale score*MS typeDuration of MS, yTreatmentMRI enhancementMS signs
* Kurtzke JF. Neurology 1983;33:1552–1555.
COHNMC = City of Hope National Medical Center; FHCRC = Fred Hutchinson Cancer Research Center; MNIH = Montreal Neurological Institute and Hospital; IFNβ-1a = interferon-beta 1a (Avonex); IFNβ-1b = interferon-beta 1-b (Betaseron); MPE = methylprednisolone; CY = cyclophosphamide; MTX = methotrexate; UMN = upper motor neuron.
139/F7.5Secondary4 (2 progressive)IFNβ-1bExtensiveAtaxia, quadriparesis,
(COHNMC)progressiveIFNβ-1acognitive decline
MPE
244/F6.5Secondary18 (3 progressive)IFNβ-1bPresentParaparesis hemiparesis,
(COHNMC)progressiveMPEUMN bladder
346/F7.0Relapsing-13IFNβ-1bPresentParaparesis, UMN bladder
(FHCRC)remittingIFNβ-1a
MPE
464/F8.5Relapsing-3IFNβ-1bContrastParaplegia, quadriparesis,
(MNIH)remittingMPEnot givenoptic neuropathies
IVIg
Plasma exchange
MPE
CY
MTX
541/F6.0Secondary16 (3 progressive)IFNβ-1bNoneParaparesis, hemifacial
(COHNMC)progressivespasm, optic neuropathy
645/F7.0Secondary20 (9 progressive)MPEPresentParaparesis, UMN bladder,
(COHNMC)progressiveAzathioprinecognitive decline
747/F5.5Secondary29 (7 progressive)IFNβ-1aNoneParaparesis, UMN bladder
(FHCRC)progressiveMPE
833/F8.0Progressive13IFNβ-1bNoneParaplegia, quadriparesis,
(FHCRC)relapsingGlatiramer acetate (Copaxone)UMN bladder
949/F6.5Secondary22 (5 progressive)IFNβ-1bNoneAtaxia, optic neuritis
(FHCRC)progressiveCY
MPE
1036/M6.0Primary1MPENoneQuadriparesis
(FHCRC)progressive